Sanara MedTech Inc. Partners with ChemoMouthpiece
Sanara MedTech Inc. (NASDAQ: SMTI) has made waves recently by forming an exclusive U.S. distribution agreement with ChemoMouthpiece, LLC, in collaboration with InfuSystem Inc. This partnership underscores Sanara's dedication to improving patient care through effective skincare solutions, especially in oncology.
The Chemo Mouthpiece is a clinically validated oral cryotherapy device aimed at easing the discomfort of oral mucositis, a painful condition that many chemotherapy patients experience. By harnessing ChemoMouthpiece's expertise, Sanara intends to offer a vital resource for patients looking for relief.
Understanding the Distribution Agreement
Under the terms of the agreement, SI Healthcare Technologies—a 50/50 joint venture between SMTI and InfuSystem—will serve as the exclusive distributor of ChemoMouthpiece's kits throughout the United States. The strategy focuses on reaching about 3,000 cancer centers through InfuSystem's established sales network. Moreover, SI Technologies will obtain these kits at a fixed cost, along with royalties based on net revenues generated from related intellectual property.
Financial Commitments and Future Options
In a notable investment move, Sanara has committed $5 million to acquire a 6.6% stake in ChemoMouthpiece. This funding will be drawn from part of the $15.5 million secured through a term loan with CRG Servicing, LLC. Importantly, SI Technologies holds the option to purchase the U.S. operations of ChemoMouthpiece, including specific intellectual properties linked to the product, with the purchase option available until January 31, 2029.
Significance of ChemoMouthpiece
Oral mucositis can lead to painful mouth sores, severely affecting the quality of life for those undergoing chemotherapy. The introduction of the Chemo Mouthpiece is expected to not only mitigate these issues but also potentially lower treatment costs for oncology centers. As a result, patients can continue their cancer therapies with enhanced comfort and support. Future studies from ChemoMouthpiece are anticipated to further validate the device's effectiveness.
Recent Developments in Sanara's Portfolio
As part of its ongoing commitment to innovation, Sanara has also secured a licensing agreement with Tufts University to develop and commercialize an exciting range of patented technologies focusing on 18 unique collagen peptides. This initiative strengthens Sanara's drive to expand its product lineup, notably including its prominent CellerateRX Surgical Powder, a bioactive collagen product noted for its clinical efficacy.
Industry Outlook for Sanara MedTech
Recent analysis indicates that the market for oral mucositis treatments is projected to experience significant growth, reaching a valuation of $1.6 billion by 2023, with a 7.1% compound annual growth rate (CAGR) expected until 2032. This promising trajectory is largely due to advances in cancer therapies and an expanding patient demographic, particularly among the elderly, who typically require specialized therapeutics.
Sanara's Stock Performance
Even with this optimistic news, shares of SMTI have encountered some difficulties over the past year, dropping by 5.8%, compared to an industry average growth of 18.4%. Investors should consider these factors when assessing Sanara's market position.
Insights on Sanara's Market Ranking
Current evaluations show that Sanara holds a Zacks Rank of #4 (Sell). Meanwhile, companies like Intuitive Surgical (NASDAQ: ISRG) and TransMedics Group (NASDAQ: TMDX) are gaining momentum. Intuitive Surgical has seen an impressive 62.2% increase in share price over the past year, while TransMedics has surged by 143.8% in the same period.
Frequently Asked Questions
What is the primary goal of Sanara's partnership with ChemoMouthpiece?
The goal of the partnership is to distribute an effective oral cryotherapy device that enhances patient comfort during chemotherapy.
How does FDA involvement affect the Chemo Mouthpiece?
The Chemo Mouthpiece is FDA 501(k) approved, ensuring its safety and effectiveness for use by patients.
What future options does SI Technologies have regarding ChemoMouthpiece?
SI Technologies can purchase the U.S. business and related intellectual properties of ChemoMouthpiece, with the option valid until January 31, 2029.
What financial commitment has Sanara made regarding ChemoMouthpiece?
Sanara has invested $5 million to acquire a 6.6% stake in ChemoMouthpiece as part of its growth strategy.
How is the oral mucositis treatment market expected to grow?
The market is projected to grow, with a forecasted CAGR of 7.1% from 2024 to 2032, driven by advancements in cancer treatment options.
